Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009971 | 0.91 | ENPP2 (0.42) | HDAC1ENPP2GRM2CTSSCTSK | |
| SCHEMBL26508626 | 0.85 | HDAC1 (0.56) | HDAC1GRM2CTSSCTSKBRD4 | |
| SCHEMBL16410213 | 0.83 | HDAC1 (0.48) | HDAC1ENPP2GRM2CTSSCTSK | |
| SCHEMBL29952891 | 0.81 | GLS (0.52) | HDAC1GRM2BRD4CREBBPGLS | |
| SCHEMBL209838 | 0.81 | GLS (0.52) | HDAC1GRM2BRD4CREBBPGLS | |
| SCHEMBL6243284 | 0.81 | HDAC1 (0.51) | HDAC1GRM2CTSSCTSKBRD4 | |
| SCHEMBL12053374 | 0.79 | TACR1 (0.41) | HDAC1ENPP2GRM2CTSSCTSK | |
| SCHEMBL12791343 | 0.78 | GRM2 (0.46) | HDAC1GRM2CTSSCTSKGLS | |
| SCHEMBL18664572 | 0.78 | GRM2 (0.54) | HDAC1GRM2CTSSCTSKBRD4 | |
| SCHEMBL30504293 | 0.77 | HDAC1 (0.56) | HDAC1CTSSCTSKBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| EP-2259681-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-2249646-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2249830-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2249647-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100166-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | HDAC1 1086/4885ENPP2 200/4885GRM2 716/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | HDAC1 956/4885ENPP2 530/4885GRM2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.